171768-67-5

Basic information

• Product Name: 4-BROMO-3-METHOXYPHENOL BENZYL ETHER
• Synonyms: 1-((4-BROMO-3-METHOXYPHENOXY)METHYL)BENZENE;4-BROMO-3-METHOXYPHENOL BENZYL ETHER;5-Benzyloxy-2-bromoanisole;4-Benzyloxy-1-bromo-2-methoxybenzene
• CAS NO: 171768-67-5
• Molecular Formula: C₁₄H₁₃BrO₂
• Molecular Weight: 293.16
• EINECS: 200-258-5
• Mol File: 171768-67-5.mol
• Article Data: 6

Chemical Properties

• Boiling Point: 377.8 °C at 760 mmHg
• Flash Point: 166.1 °C
• Appearance: /
• Density: 1.367 g/cm³
• Vapor Pressure: 1.43E-05mmHg at 25°C
• Refractive Index: 1.584
• CAS DataBase Reference: 4-BROMO-3-METHOXYPHENOL BENZYL ETHER(CAS DataBase Reference)
• NIST Chemistry Reference: 4-BROMO-3-METHOXYPHENOL BENZYL ETHER(171768-67-5)
• EPA Substance Registry System: 4-BROMO-3-METHOXYPHENOL BENZYL ETHER(171768-67-5)

Safety Data

• Hazardous Substances Data: 171768-67-5(Hazardous Substances Data)

Usage

General Description

4-Bromo-3-methoxyphenol Benzyl Ether is a chemical compound that falls under the class of aromatic ethers. 4-BROMO-3-METHOXYPHENOL BENZYL ETHER, as the name implies, contains a benzyl ether component, which is an organic compound with the general formula R-O-R' where the oxygen atom is connected to an aryl or alkyl group. The “4-Bromo-3-methoxyphenol” part of the name signifies that the compound also includes a bromine atom (a common halogen in chemistry) and a methoxy group, which is the functional group containing a methyl group bonded to an oxygen atom. This chemical may be used in the field of organic synthesis. As with most chemical substances, precautions should be taken to handle it properly due to potential risks and hazards.

InChI:InChI=1/C14H13BrO2/c1-16-14-9-12(7-8-13(14)15)17-10-11-5-3-2-4-6-11/h2-9H,10H2,1H3

Upstream product

• 21144-16-1 3-benzyloxyanisole 
• 102127-34-4 4-bromo-3-methoxyphenol 
• 100-39-0 benzyl bromide 
• 100-44-7 benzyl chloride 

Downstream Products

• 948571-54-8 tert-butyl [4-(benzyloxy)-2-methoxyphenyl]acetate 
• 1437776-48-1 1-(azetidin-1-yl)-2-[4-(2-{(1S,2R)-2-[1-(5-chloropyrimidin-2-yl)piperidin-4-yl]cyclopropyl}ethoxy)-2-methoxyphenyl]ethanone 
• 1437778-87-4 1-(azetidin-1-yl)-2-(4-hydroxy-2-methoxyphenyl)ethanone 
• 1437778-86-3 1-(azetidin-1-yl)-2-[4-(benzyloxy)-2-methoxyphenyl]ethanone 
• 863310-59-2 [4-(benzyloxy)-2-methoxyphenyl]acetic acid 
• 1376514-53-2 methyl 2-[4-(benzyloxy)-2-methoxybenzyl]-3-oxobutanoate 
• 1376514-61-2 5-[4-(benzyloxy)-2-methoxybenzyl]-N₄-[(3S)-1-{[tert-butyl(dimethyl)silyl]oxy}hexan-3-yl]-6-methylpyrimidine-2,4-diamine 
• 1376514-63-4 4-[(2-amino-4-{[(3S)-1-{[tert-butyl(dimethyl)silyl]oxy}hexan-3-yl]amino}-6-methyl-pyrimidin-5-yl)methyl]-3-methoxyphenol 
• 1376514-59-8 (3S)-3-({2-amino-5-[4-(benzyloxy)-2-methoxybenzyl]-6-methylpyrimidin-4-yl}amino)-hexan-1-ol 
• 1376514-57-6 2-amino-5-[4-(benzyloxy)-2-methoxybenzyl]-6-methylpyrimidin-4-yl 2,4,6-triisopropylbenzenesulfonate 
• 1376514-55-4 2-amino-5-[4-(benzyloxy)-2-methoxybenzyl]-6-methylpyrimidin-4-ol 
• 1376514-65-6 (3S)-3-[(2-amino-5-{4-[2-(dimethylamino)ethoxy]-2-methoxybenzyl}-6-methylpyrimidin-4-yl)amino]hexan-1-ol 
• 211495-28-2 4-benzyloxy-2-methoxy-phenylboronic acid 

Relevant articles and documents

TETRASUBSTITUTED ALKENE COMPOUNDS AND THEIR USE

Disclosed herein are compounds, or pharmaceutically acceptable salts thereof, and methods of using the compounds for treating breast cancer by administration to a subject in need thereof a therapeutically effective amount of the compounds or pharmaceutically acceptable salts thereof. The breast cancer may be an ER-positive breast cancer and/or the subject in need of treatment may express a mutant ER-α protein.

Visible-light photoredox catalysis enabled bromination of phenols and alkenes

A mild and efficient methodology for the bromination of phenols and alkenes has been developed utilizing visible light-induced photoredox catalysis. The bromine was generated in situ from the oxidation of Br- by Ru(bpy)33+, both of which resulted from the oxidative quenching process.

2-AMINO-6-(2-SUBSTITUTED-4-PHENOXY)-SUBSTITUTED-PYRIDINES

This present invention relates to compounds of the formula wherein G, R1 and R2 are defined as in the specification, to pharmaceutical compositions containing them and to their use in the treatment and prevention of central nervous system and other disorders.